Fungal laryngitis is common in immunocompromised patients. But it is rarely seen in a immunocompetent person. Only around 40 cases have been reported in world literature so far. This condition is often confused with premalignant con ditions like leukoplakia, dysplasia. Our patient, a 35 years old immuno competent male, presented with hoarseness, who later on developed stridor and had to be tracheostomized. Laryngoscopy was done under general anesthesia and biopsy taken. Histopathological examination revealed fungal laryngitis (Aspergillus). The patient recovered completely after antifungal treatment.
INTRODUCTION
Fungal laryngitis is often seen in immunocompromised patients but is often overlooked in an immunocompetent patient. It is more often than not mistaken for leukoplakia or dysplasia of the vocal folds. Around 40 cases of fungal laryngitis have been reported in immunocompetent persons in world literature. 1 The examiner needs to have a sufficient degree of suspicion in order to diagnose fungal laryngitis (in nonimmunocompromised), which could be superficial or invasive.
CASE HISTORY
Mr RS, a 35-year-old man presented with the main complaint of hoarseness for the last 2 months and dyspnea on exertion for last 2 weeks. He was exa mined in the OPD and the only finding was white patches on both the vocal folds. The vocal folds were also edematous. We thought of differential diagnosis of leukoplakia, granulomatous conditions and fungal infections. The patient was investigated. There was no abnormality in the blood picture. The The white slough like material from the surface of the vocal folds were removed. Underlying soft tissue from the vocal folds were taken for histopathological examination. There was extension of the slough to subglottis which was the probable cause of the increase in respiratory difficulty (Fig. 1) .
The histopathological examination report revealed fungal hyphae in the mucosa and submucosa.
The fungus was identified as Aspergillus.
The patient was treated with antifungals. Initially, we started with IV Voriconazole at the dose of 200 mg twice daily. After 5 days, there was a miraculous improve ment. We then converted it to the oral form and sent the patient home with the tracheostomy. His liver function test was monitored. He came back after a month and his larynx on examination looked normal. His tracheostomy was closed. But as he could not afford Voriconazole we converted the antifungal to Itraconazole (200 mg twice daily). He continued antifungals for 3 months. At the end of 3 months (Fig. 3) , the patient was symptom free and we stopped all antifungals and have kept him on regular follow-up.
DISCUSSION
Fungal infection of the larynx is quite common in immunocompromised patients but fungal laryngitis in immunocompetent person is uncommon. In fact, only around 40 cases have been reported in world litera ture. Although, mycotic infection can occur in immunocomprised patients, sometimes these infections may be seen in the immunocompetent host in whom there are alterations in the mucosal barrier. 1 The most common fungi causing laryngitis is Candida. 1, 3 Other fungal infections like Aspergillosis, cryptococcal, blastomycosis, histoplasmosis are impli cated. All strains of Aspergillus are not tissue invasive. Only those species that grow at 37°C are tissue invasive. A definitive diagnosis is made by the demonstration of fungal spores or hyphae either by tissue biopsy or in KOH smear. Hematoxylin and eosin (H&E) stain shows epithelial hyperplasia with hyperkeratosis, neutrophil 
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within the upper epithelial layers, lymphocytes, plasma cells and scarring in (Fig. 2 ) the submucosal stroma. Periodic acid schiff stain brings out the fungal elements better than H&E stain. Asp ergillosis has septate hyphae with acute angle branching in a necrotic lesion. Treatment of fungal laryngitis is by antifungal medication either orally or intravenous. Voriconazole, itraconazole or posaconazole is administered for 3 months for invasive disease. Voriconazole and itra cona zole are administered at a dose of 200 mg twice daily while posaconazole is administered at 400 mg twice daily. Our patient was also put on antifungal medication for 3 months. All these antifungals are effective against Aspergillus. Cessation of treatment depends on the clinical absence of fungal infection. 6 At completion of 3 months our patient was disease free clinical and now on regular follow-up without any signs of recurrence.
